Skip to main content

Table 2 MPA exposure in MMF-treated systemic sclerosis. The mean and median MPA exposure correlated to MMF intake in a dose-dependent manner. There was a considerable inter-individual variation in MPA exposure in all three subgroups

From: Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study

Daily dose MMF

MPA_AUC0–12 (mg h/L)

MPA_AUC3g (mg h/L) (n = 34)

0.5 g × 2 (n = 5)

1 g × 2 (n = 21)

1.5 g × 2 (n = 8)

All subjects (n = 34)

Mean

50

75

102

78

115

Median

48

72

119

72

114

Interquartile range

33–69

60–86

72–135

58–102

87–139

Range

25–75

43–120

27–139

25–139

27–226

  1. MPA_AUC0–12 mycophenolate acid area under the concentration-time curve 0–12 h (mg h/L), MMF mycophenolate mofetil
  2. MPA_AUC3g MPA_AUC0–12 adjusted to a daily intake of 1.5 g MMF twice daily (mg h/L)